⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4189951 | 0.74 | — | — | |
| SCHEMBL4194266 | 0.72 | — | — | |
| SCHEMBL15096660 | 0.72 | — | — | |
| SCHEMBL691776 | 0.70 | — | — | |
| L-Sulforaphane SCHEMBL29370377 | 0.69 | NAAA (0.50) | — | |
| Sulforaphane SCHEMBL20855320 | 0.69 | NAAA (0.50) | — | |
| Sulforaphane SCHEMBL105202 | 0.69 | NAAA (0.50) | — | |
| Sulforaphane SCHEMBL17629812 | 0.69 | NAAA (0.50) | — | |
| Sulforaphane SCHEMBL15822685 | 0.69 | NAAA (0.50) | — | |
| Sulforaphane SCHEMBL105203 | 0.69 | NAAA (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326056-A1 | NOVEL ACTIVES AGAINST PROSTATE CARCINOMA | DSM IP ASSETS B.V. (NL) | 2009-12-31 | — | — | US | claimed |
| EP-1569628-B1 | NOVEL USE OF LYCOPENE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ANDROGEN SIGNALLING | DSM IP ASSETS BV (NL) | 2009-07-22 | — | — | EP | claimed |
| US-20060069151-A1 | Novel use of lycopene | DSM IP ASSETS B.V. (NL) | 2006-03-30 | — | — | US | claimed |
| US-20060020046-A1 | Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies | DMS IP ASSETS B.V. (NL) | 2006-01-26 | — | — | US | claimed |
| EP-1569628-A1 | NOVEL USE OF LYCOPENE | DSM IP Assets B.V. (NL) | 2005-09-07 | — | — | EP | claimed |
| EP-1476143-A1 | COMPOSITIONS COMPRISING LYCOPENE FOR THE TREATMENT AND PREVENTION OF ANGIOGENESIS ASSOCIATED PATHOLOGIES | DSM IP Assets B.V. (NL) | 2004-11-17 | — | — | EP | claimed |
| WO-2004052351-A1 | NOVEL USE OF LYCOPENE | DSM IP ASSETS B.V. (CH) | 2004-06-24 | — | — | WO | claimed |
| WO-2003068202-A1 | COMPOSITIONS COMPRISING LYCOPENE FOR THE TREATMENT AND PREVENTION OF ANGIOGENESIS ASSOCIATED PATHOLOGIES | DSM IP ASSETS B.V. (NL) | 2003-08-21 | — | — | WO | claimed |
| US-20090326056-A1 | NOVEL ACTIVES AGAINST PROSTATE CARCINOMA | DSM IP ASSETS B.V. (NL) | 2009-12-31 | — | — | US | disclosed |
| EP-1569628-B1 | NOVEL USE OF LYCOPENE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ANDROGEN SIGNALLING | DSM IP ASSETS BV (NL) | 2009-07-22 | — | — | EP | disclosed |
| EP-2020997-A2 | NOVEL ACTIVES AGAINST PROSTATE CARCINOMA | DSMIP Assets B.V. (NL) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007131767-A2 | NOVEL ACTIVES AGAINST PROSTATE CARCINOMA | DSM IP ASSETS B.V. (NL) | 2007-11-22 | — | — | WO | disclosed |
| US-20060069151-A1 | Novel use of lycopene | DSM IP ASSETS B.V. (NL) | 2006-03-30 | — | — | US | disclosed |
| US-20060020046-A1 | Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies | DMS IP ASSETS B.V. (NL) | 2006-01-26 | — | — | US | disclosed |
| EP-1569628-A1 | NOVEL USE OF LYCOPENE | DSM IP Assets B.V. (NL) | 2005-09-07 | — | — | EP | disclosed |
| EP-1476143-A1 | COMPOSITIONS COMPRISING LYCOPENE FOR THE TREATMENT AND PREVENTION OF ANGIOGENESIS ASSOCIATED PATHOLOGIES | DSM IP Assets B.V. (NL) | 2004-11-17 | — | — | EP | disclosed |
| WO-2004052351-A1 | NOVEL USE OF LYCOPENE | DSM IP ASSETS B.V. (CH) | 2004-06-24 | — | — | WO | disclosed |
| WO-2003068202-A1 | COMPOSITIONS COMPRISING LYCOPENE FOR THE TREATMENT AND PREVENTION OF ANGIOGENESIS ASSOCIATED PATHOLOGIES | DSM IP ASSETS B.V. (NL) | 2003-08-21 | — | — | WO | disclosed |